BrightGene Bio (China) Top Management

BrightGene Bio Management Team Effectiveness

The company has return on total asset (ROA) of 0.0227 % which means that it generated a profit of $0.0227 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.06 %, meaning that it generated $0.06 on every $100 dollars invested by stockholders. BrightGene Bio's management efficiency ratios could be used to measure how well BrightGene Bio manages its routine affairs as well as how well it operates its assets and liabilities. At present, BrightGene Bio's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 3.9 B, whereas Net Tangible Assets are forecasted to decline to about 1.2 B. As of January 14, 2025, Common Stock Shares Outstanding is expected to decline to about 340.7 M. In addition to that, Net Income Applicable To Common Shares is expected to decline to about 141.5 M

BrightGene Bio Workforce Comparison

The company has Profit Margin (PM) of 0.15 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.26 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.26.

BrightGene Bio Medical Benchmark Summation

BrightGene Bio Notable Stakeholders

The success or failure of an entity such as BrightGene Bio Medical often depends on how effective the management is. BrightGene Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BrightGene management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BrightGene management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of BrightGene Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BrightGene Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of BrightGene Bio's management manipulating its earnings.

When running BrightGene Bio's price analysis, check to measure BrightGene Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BrightGene Bio is operating at the current time. Most of BrightGene Bio's value examination focuses on studying past and present price action to predict the probability of BrightGene Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BrightGene Bio's price. Additionally, you may evaluate how the addition of BrightGene Bio to your portfolios can decrease your overall portfolio volatility.